
What is claimed is:

1. A pharmaceutical composition ~~for treating a subject suffering from an androgen receptor associated medical condition,~~ comprising:

a compound selected from the group consisting of a compound according to formula VI ~~and formula VII~~:



VI

wherein R_1 and R_2 are each independently selected from a methoxy group, a hydroxyl group, and an alkyl sulfonyl group;


L is a carbonyl, alkylene, or alkenylene, or alkynl when Z is not present;

Z is -OH, a substituted styrenyl, a cycloalkyl, $-COR_3$, $-CONR_3R_4$, or $-CX_3$, wherein R_3 and R_4 are each –H, $-CH_3$, $-C_nH_{2n+1}$ wherein n = 2-4, a heterocyclic, a heteroaryl, or a cycloalkyl, or R_3 and R_4 together form a heterocyclic; or Z is COOR wherein R is -H, $-CH_3$, or a cycloalkyl;

X is a halo;

Y is an alkyl, or a halo,

a compound according to formula VII:



VII

wherein R_1 and R_2 are each independently ~~mono- or di-substituted groups, such as~~ selected from a methoxy group ~~($-OCH_3$)~~, a hydroxyl group ~~(-OH)~~, ~~or~~ and an alkyl sulfonyl group~~, such as~~

~~$-OSO_2C_2H_5$; R_1 and R_2 could be the same or different~~;


L is a carbonyl, alkylene, or alkenylene, or alkynl when Z is not present;

Z is -H, -OH, a substituted styrenyl, an aromatic ring, a cycloalkyl, $-COR_3$, $-CONR_3R_4$, or $-CX_3$, wherein R_3 and R_4 are each ~~-~~H, $-CH_3$, $-C_nH_{2n+1}$ wherein n = 2-4, ~~-c or~~ a heterocyclic, ~~or~~ a heteroaryl ~~moiety~~, or a cycloalkyl or R_3 and R_4 together ~~to~~ form a heterocyclic ~~ring~~, ~~such as a morpholine~~; or Z is COOR, wherein R is -H, $-CH_3$, $-C_nH_{2n+1}$, wherein (n = 2-4), or a cycloalkyl, when Y is not H;

X is a halo, ~~-F, -Cl, or -Br;~~

Y is H, ~~when L is an alkylene, such as $-CH_2$, and Z is $-CONR_3R_4$, R_3 and R_4 are each -H and a heterocyclic or a heteroaryl, or a cycloalkyl, such as a cyclopentanyl; or Y is a~~ an ~~short~~ alkyl ~~(C1-3), such as a methyl ($-CH_3$),~~ or a halo ~~F, Cl, Br,~~ and ~~further wherein said pharmaceutical composition treats said subject suffering from said androgen receptor associated medical condition.~~

a compound according to formula VIII:




VIII

wherein:

R_1 and R_2 are each independently selected from a methoxy group, a hydroxyl group and an alkyl sulfonyl group;

R_3 is selected from the group consisting of



; and

R_4 is selected from the group consisting of an alkyl and a halo; and

n is 1 or 2;

wherein each phenyl of the compounds according to formula VI, VII, or VIII is mono- or di-substituted by R_1 or R_2.


2. The pharmaceutical composition according to claim 1, further comprising a pharmaceutically acceptable carrier. ~~wherein said androgen receptor associated medical condition is an androgen receptor associated medical condition that is induced, caused or mediated by a normal or abnormal androgen receptor.~~

3. The pharmaceutical composition according to claim 1 or 2, for use in the treatment of an ~~wherein said~~ androgen receptor associated medical condition selected from an unwanted immune response, an immune disorder, inflammation, acne, alopecia, hirsutism, a wound, Spinal and Bulbar Muscular Atrophy (SBMA, Kennedy's Disease) and cancer. ~~is inflammation~~.

4. The pharmaceutical composition according to claim 3~~1~~, wherein said cancer is selected from prostrate cancer, bladder cancer, liver cancer, breast cancer, pancreatic cancer, and ovarian cancer. ~~androgen receptor associated medical condition is acne.~~

5. Use of a ~~The~~ pharmaceutical composition according to claim 1 in the manufacture of a medicament for treating a subject suffering from, ~~wherein said~~ an androgen receptor associated medical condition ~~is alopecia~~.

6. A compound of formula (VI):



(VI),

wherein

R_1 and R_2 are each independently selected from a methoxy group, a hydroxyl group, and an alkyl sulfonyl group;

L is a carbonyl, alkylene, or alkenylene, or alkynl when Z is not present;

Z is -OH, a substituted styrenyl, a cycloalkyl, $-COR_3$, $-CONR_3R_4$, or $-CX_3$, wherein R_3 and R_4 are each –H, $-CH_3$, $-C_nH_{2n+1}$ wherein n = 2-4, a heterocyclic,


a heteroaryl, or a cycloalkyl, or R_3 and R_4 together form a heterocyclic, and wherein X is a halo; or Z is COOR wherein R is -H, $-CH_3$, or a cycloalkyl; and

Y is an alkyl or a halo,

wherein each phenyl of the compound is mono- or di-substituted by R_1 or R_2.

~~The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is hirsutism.~~

7. A compound of formula VII:



VII

wherein R_1 and R_2 are each independently selected from a methoxy group, a hydroxyl group, and an alkyl sulfonyl group;

L is a carbonyl, alkylene or alkenylene; or alkynl when Z is not present;

Z is -H, -OH, a substituted styrenyl, an aromatic ring, a cycloalkyl, $-COR_3$, $-CONR_3R_4$, or $-CX_3$, wherein R_3 and R_4 are each –H, $-CH_3$, $-C_nH_{2n+1}$ wherein n = 2-4, a heterocyclic, a heteroaryl, or a cycloalkyl, or R_3 and R_4 together form a heterocyclic; or Z is COOR wherein R is -H, $-CH_3$, $-C_nH_{2n+1}$, wherein n = 2-4, or a cycloalkyl, when Y is not H;


X is a halo;

Y is H, an alkyl, or a halo,

wherein each phenyl of the compound is mono- or di-substituted by R_1 or R_2.

~~The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is a wound.~~

8. A compound according to formula VIII:




VIII

wherein:

R_1 and R_2 are each independently selected from a methoxy group, a hydroxyl group, and an alkyl sulfonyl group;

R_3 is selected from the group consisting of



; and


R_4 is selected from the group consisting of an alkyl and a halo; and

n is 1 or 2,

wherein each phenyl of the compound is mono- or di-substituted by R_1 or R_2.

~~The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is Spinal and Bulbar Muscular Atrophy (SBMA, Kennedy's Disease).~~

9. A compound of formula (VI):



(VI),

wherein

R_1 and R_2 are each independently selected from a methoxy group, a hydroxyl group, and an alkyl sulfonyl group;

L is a carbonyl, alkylene, or alkenylene, or alkynl when Z is not present;

Z is -H, -OH, a substituted styrenyl, a cycloalkyl, $-COR_3$, $-CONR_3R_4$, or $-CX_3$, wherein R_3 and R_4 are each –H, $-CH_3$, $-C_nH_{2n+1}$ wherein n = 2-4, a heterocyclic, a heteroaryl, or a cycloalkyl, or R_3 and R_4 together form a heterocyclic, and wherein X is a halo; or Z is COOR wherein R is -H, $-CH_3$, $-C_nH_{2n+1}$, wherein n = 2-4; and

Y is an alkyl,


wherein each phenyl of the compound is mono- or di-substituted by R_1 or R_2.

~~The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is cancer.~~

10. The compound of claim 9, wherein each of R_1 and R_2 is $-OCH_3$, L is an alkylene, Z is COOR, R being $-C_nH_{2n+1}$, wherein n = 2-4, and Y is an alkyl.

~~The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is prostate cancer.~~


11. The compound of claim 9, wherein L and Z together form a group selected from



; and

~~The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is bladder cancer.~~


12. The compound of claim 9, wherein the compound is



.

~~The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is liver cancer.~~

13. A compound of formula (VII):



VII

(VII),

wherein

R_1 and R_2 are each independently selected from a methoxy group, a hydroxyl group, and an alkyl sulfonyl group;

L is a carbonyl, alkylene, or alkenylene, or alkynl when Z is not present;

Z is -H, -OH, a substituted styrenyl, a cycloalkyl, $-COR_3$, $-CONR_3R_4$, or $-CX_3$, wherein R_3 and R_4 are each –H, $-CH_3$, $-C_nH_{2n+1}$ wherein n = 2-4, a heterocyclic, a heteroaryl, or a cycloalkyl, or R_3 and R_4 together form a heterocyclic, and wherein X is a halogen; or Z is COOR wherein R is -H, $-CH_3$, $-C_nH_{2n+1}$, wherein n = 2-4; and

Y is an alkyl,


wherein each phenyl of the compound is mono- or di-substituted by R_1 or R_2.

~~The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is breast cancer.~~

14. The compound of claim 13, wherein each of R_1 and R_2 is $-OCH_3$, L is an alkylene, Z is COOR, R being $-C_nH_{2n+l}$, wherein n = 2-4, and Y is an alkyl.

~~The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is pancreatic cancer.~~

15. The compound of claim 13, wherein L and Z together form a group selected from



; and

~~The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is ovarian cancer.~~

16. A pharmaceutical composition for treating a subject suffering from an androgen receptor associated medical condition, the pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to one of Claims 9 to 15, wherein the androgen receptor associated medical condition is selected from inflammation, acne, alopecia, hirsutism, wound, Spinal and Bulbar Muscular Atrophy (SBMA, Kennedy's Disease), unwanted immune response, immune disorder, and cancer.

~~The pharmaceutical composition according to claim 1, wherein said compound according to formula VI comprises a pharmaceutically acceptable carrier.~~

17. Use of a compound according to one of Claims 9 to 15 in the manufacture of a medicament for treating an androgen receptor associated medical condition, wherein the androgen receptor associated medical condition is selected from inflammation, acne, alopecia, hirsutism, wound, Spinal and Bulbar Muscular Atrophy (SBMA, Kennedy's Disease), unwanted immune response, immune disorder, and cancer.

~~The pharmaceutical composition according to claim 1, wherein said subject is human.~~

18. Use of a compound according to one of Claims 6 to 8 in the manufacture of a medicament for treating an androgen receptor associated medical condition, wherein the androgen receptor associated medical condition is selected from inflammation, acne, alopecia, hirsutism, wound, Spinal and Bulbar Muscular Atrophy (SBMA, Kennedy's Disease), unwanted immune response, immune disorder, and cancer.

~~The pharmaceutical composition according to claim 1, wherein said subject is non-human.~~

~~19. The pharmaceutical composition according to claim 1, wherein said subject is a patient.~~


~~20. The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is an unwanted immune response.~~

~~21. The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is an immune disorder.~~

~~22. The pharmaceutical composition according to claim 1, wherein said pharmaceutical composition is provided in a therapeutically effective amount.~~

~~23. A pharmaceutical composition for treating a subject suffering from an androgen receptor associated medical condition, comprising:~~

~~a compound according to formula VIII:~~




VIII

~~wherein:~~

~~R_1 and R_2 are mono- or di-substituted groups, such as a methoxy group (-OCH_3), a hydroxyl group (-OH), or an alkyl sulfonyl group, such as -$OSO_2C_2H_5$; R_1 and R_2 could be the same or different;~~

~~R_3 is selected from the group consisting of~~



~~R_4 is selected from the group consisting of CH_3, H, F and Cl;~~

~~n is 1 or 2; and~~

~~further wherein said pharmaceutical composition treats said subject suffering from said androgen receptor associated medical condition.~~

~~24. A method of treating a subject suffering from an androgen receptor associated medical condition, comprising:~~

~~a) providing a subject; and~~

~~b) administering to said patient, a therapeutically effective amount of a compound according to claim 1.~~

~~25. A method of treating a subject suffering from an androgen receptor associated medical condition, comprising:~~

~~a. providing a subject; and~~

~~b. administering to said patient, a therapeutically effective amount of a compound according to claim 23.~~